Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs

Journal of Medicinal Chemistry

Volumn 42, Issue 6, 1999, Pages 1076-1087

  Nakazato, Atsuro ^a   Ohta, Kohmei ^a   Sekiguchi, Yoshinori ^a   Okuyama, Shigeru ^a   Chaki, Shigeyuki ^a   Kawashima, Yutaka ^a   Hatayama, Katsuo ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 DIPROPYLAMINOETHYL) 4 METHOXY 6H DIBENZO[B,D]PYRAN; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; APOMORPHINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LIGAND; METHAMPHETAMINE; N ALLYLNORMETAZOCINE; N,N DIPROPYL 2 (4 METHOXY 3 BENZYLOXYLPHENYL)ETHYLAMINE; NEUROLEPTIC AGENT; OPIATE RECEPTOR AFFECTING AGENT; PHENYLALKYLAMINE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANISOLES; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LIGANDS; MALE; MICE; MICE, INBRED ICR; PROPYLAMINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033602524     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980212v     Document Type: Review

References (57)

1. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; DeCosta, B.; Rice, K. C. σ Receptors: Biology and Function. Pharmacol. Rev. 1990, 42, 355-402.
2. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The Effects of Morphine-like and Nalorphine-like Drugs in Nondependent and Morphine Dependent Chronic Spinal Dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-632.
3. 3H]-Haloperidol Binding in Guinea Pig Brain Membranes. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 5618-21.
4. Itzhak, Y. Pharmacological Specificity of Some Psychotomimetic and Antipsychotic Agents for the σ and PCP Binding Sites. Life Sci. 1988, 42, 745-752.
5. Largent, B. L.; Wikström, H.; Snowman, A. M. Novel Antipsychotic Drug Share High Affinity for σ Receptors. Eur. J. Pharmacol. 1988, 156, 345-347.
6. Ferris, R. M.; Harfenist, M.; McKenzie, G. M.; Cooper, B.; Soroko, F. E.; Maxwell, R. A. BW 234U, (Cis-9-[3-(3,5-Dimethyl-1-Piperazinyl)Propyl]Carbazole Dihydrochloride): a Novel Antipsychotic Agent. J. Pharm. Pharmacol. 1982, 34, 388-390.
7. Davidson, J.; Miller, R.; Wingfield, M.; Zung, W.; Dren, A. T. The First Clinical Study of BW-234U in Schizophrenia. Psychopharmacol. Bull. 1982, 18, 173-176.
8. Guy, W.; Manov, G.; Wilson, W. H.; Ban, T. A.; Fjetland, O. K.; Manberg, P. J.; Dren, A. T. Psychotropic Action of BW 234U in the Treatment of Inpatient Schizophrenics: A Dose-range Study. Drug Dev. Res. 1983, 3, 245-252.
9. Chouinard, G.; Annable, L. An Early Phase II Clinical Trial of BW 234U in the Treatment of Acute Schizophrenia in Newly Admitted Patients. Psychopharmacology 1984, 84, 282-284.
10. Schwarcz, G.; Halaris, A.; Dren, A.; Manberg, P. Open Label Evaluation on the Novel Antipsychotic Compound BW 234U in Chronic Schizophrenics. Drug Dev. Res. 1985, 5, 387-393.
11. Ferris, R. M.; Tang, F. L. M.; Russell, A.; Harfenisty, M. Rimcazole (BW 234U), a Novel Antipsychotic Agent Whose Mechanism of Action Can Not Be Explained by a Direct Blockade of Postsynaptic Dopaminergic Receptors in Brain. Drug Dev. Res. 1986, 9, 171-188.
12. Ferris, R. M.; Tang, F. L. M.; Chang, K. J.; Russell, A. Evidence that the Potential Antipsychotic Agent, Rimcazole (BW 234U), Is a Specific, Competitive Antagonist of σ Sites in the Brain. Life Sci. 1986, 38, 2329-2337.
13. Ceci, A.; Smith, M.; French, E. D. Activation of the A10 Mesolimbic System By the σ Receptor Antagonist (+(-SKF-10047 can be Blocked By Rimcazole, a Novel Putative Antipsychotic. Eur. J. Pharmacol. 1988, 154, 53-57.
14. Ogren, S. O.; Hall, H.; Köhler, C.; Magnusson, O.; Lindbom, L. O.; Angeby, K.; Florvall, L. Remoxipride, a New Potential Antipsychotic Compound with Selective Anti-dopaminergic Actions in the rat brain. Eur. J. Pharmacol. 1984, 102, 459-474.
15. Lindström, L.; Besev, G.; Stening, G.; Widerlöv, E. An Open Study of Remoxipride, a Benzamide Derivative, in Schizophrenia. Psychopharmacology 1985, 86, 241-243.
16. McCreadie, R. G.; Morrison, D.; Eccleston, D.; Gall, R. G.; Loudon, J.; Mitchell, M. J. An Open Multicentre Study of the Treatment of Floide Schizophrenia with Remoxipride. Acta Psychiatr. Scand. 1985, 72, 139-143.
17. den Boer, J. A.; Verhoeven, W. M. A.; Westenberg, H. G. M. Remoxipride in Schizophrenia. A Preliminary Report. Acta Psychiatr. Scand. 1986, 74, 409-414.
18. Laursen, A. L.; Gerlach, J. Antipsychotic Effect of Remoxipride, a New Substituted Benzamide with Selective Antidopaminergic Activity. Acta Psychiatr. Scand. 1986, 73, 863-979.
19. Wadworth, A. N.; Heel, R. C. Remoxipride. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Schizophrenia. Drugs 1990, 40, 863-879.
20. 2 Dopamine Sites. Soc. Neurosci. Abstr. 1985, 11, 114.
21. Taylor, D. P.; Dekleva, J. Potential Antipsychotic BMY 14802 Selectively Binding to σ Sites. Drug Dev. Res. 1987, 11, 65-70.
22. Karbon, E. W.; Abreu, M .E.; Erickson, R. H.; Kaiser, C.; Natalie, Jr., K. J.; Clissold, D. B.; Borosky, S.; Bailey, M.; Martin, L. A.; Pontecorvo, M. J.; Enna, S.; Ferkany, J. W. NPC16377, a Potent and Selective σ-ligand. I. Receptor Binding, Neurochemical and Neuroendocrine profile. J. Pharmacol. Exp. Ther. 1993, 265, 866-875.
23. Hock, F. J.; Kruse, H.; Gerhards, H. J.; Konz, E. Pharmacological Effects of HR 375: a New Potential Antipsychotic Agent. Drug Dev. Res. 1985, 6, 301-311.
24. 2 Receptor Antagonist: Receptor-binding, Electrophysiological and Neuropharmacological profiles. J. Pharmacol. Exp. Ther. 1992, 263, 1167-1174.
25. Gilligan, P. J.; Cain, G. A.; Christos, T. E.; McElroy, J. F.; Zaczek, R.; Tam, S. W. σ-selective Antagonists as Potential Antipsychotic Drugs: S.A.R. and Pharmacology. XIIth International Symposium on Medicinal Chemistry, Basel, Switzerland, 1992.
26. Gilligan, P. J.; Cain, C. A.; Christons, T. E.; Cook, L.; Drummond, S.; Johnson, A. L.; Kergaye, A. A.; McElroy, J. F.; Rohrbach, K. W.; Schmidt, W. K.; Tam, S. W. Novel Piperidine σ Receptor Ligands as Potential Antipsychotic Drugs. J. Med. Chem. 1992, 35, 4344-4361.
27. Poncelet, M; Santucci, V.; Paul, R.; Gueudet, C.; Lavastre, S.; Guitard, J.; Steinberg, R.; Terranova, J. P.; Breliere, J. C.; Soubrie, P.; Le Fur, G. Neuropharmacological Profiles of Novel and Selective Ligands of the σ sites: SR 31742A. Neuropharmacology 1993, 32, 605-615.
28. Tam, S. W.; Zhang, A. Z. s and PCP Recepters in Human Frontal Cortex Membranes. Eur. J. Pharmacol. 1988, 154, 343-344.
29. Erickson, R. D.; Natalie, Jr, K. J.; Bock, W.; Lu, Z.; Farzin, F.; Sherrill, R. G.; Meloni, D. J.; Patch, R. J.; Rzesotarski, W. J.; Clifton, J.; Pontecorvo, M., J.; Baily, M. A.; Naper, K.; Karbon, W. (Aminoalkoxy)chromones. Selective σ Receptor Ligands. J. Med. Chem. 1992, 35, 1526-1535.
30. Russell, M. G.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Noble, A. J. Benz[f]isoquinoline Analogues as High-Affinity σ Ligands. J. Med. Chem. 1992, 35, 2025-2033.
31. Carroll, F. I.; Abraham, P.; Parham, K.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Martin, B. R.; May, E. L.; Sauss, C.; Di Paolo, L.; Wallace, P.; Walker, J. M.; Bowen, W. D. Enantiomeric N-Substituted N-Normetazocines: A Comparative Study of Affinities at σ, PCP, and Opioid Receptors. J. Med. Chem. 1992, 55, 2812-2818.
32. Chambers, M. S.; Baker, R.; Billington, D. C.; Knight, A. K.; Middlemiss, D. N.; Wong, E. H. F. Spiropiperidines as High-Affinity, Selective σ Ligands. J. Med. Chem. 1992, 35, 2033-2039.
33. Yevich, J. P.; New, J. S.; Lobeck, W. G.; Dextraze, P.; Bernstein, E.; Taylor, D. P.; Yocca, F. D.; Eison, M. S.; Temple, D. L., Jr. Synthesis and Biological Characterization of a-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and Analogues as Potential Atypical Antipsychotic Agents. J. Med. Chem. 1992, 35, 4516-4525.
34. Costa, B. R.; Mattoson, M. V.; George, C.; Linders, J. T. M. Synthesis, Configuration, and Activity of Isomeric 2-Phenyl-2-(N-piperidinyl)bicyclo[3.1.0]hexanes at Phencyclidine and σ Binding Sites. J. Med. Chem. 1992, 35, 4704-4712.
35. Mewshaw, R. E.; Sherrill, R. G.; Mathew, R. M.; Kaiser, C.; Bailey, M. A.; Karbon, E. W. Synthesis and in Vitro Evaluation of 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indoles: High-Affinity Ligands for the N,N′-Di-o-tolylguanidine-Labeled σ Binding Site. J. Med. Chem. 1993, 36, 343-352.
36. 2 Binding Site. 1. 3-(ω-Aminoalkyl)-1H-indoles. J. Med. Chem. 1995, 38, 1998-2008.
37. 2 Binding Site. 2. Spiro-Joined Benzofuran, Isobenzofuran, and Benzopyran Piperidines. J. Med. Chem. 1995, 38, 2009-2017.
38. Danso-Danquah, R.; Bai, X.; Zhang, X.; Mascarella, S. W.; Williams, W.; Sine, B.; Bowen, D. W.; Carroll, F. I. Synthesis and σ Binding Properties of 1′,3′-Dihalo-N-normetazocine Analogues. J. Med. Chem. 1995, 38, 2986-2989.
39. 1 Receptors. J. Med. Chem. 1998, 41, 468-477.
40. Largent, B. L.; Wikstrom, H.; Gundlach, A. L.; Snyder, S. H. Structural Determinants of a Receptor Affinity. Mol. Pharmacol. 1987, 32, 772-784.
41. Pettersson, I.; Liljefors, T. Structure-activity Relationships for Apomorphine Congeners. Conformatioal Energies vs Biological Activities. J. Comput.-Aided Mol. Design 1987, 7, 143-152.
42. Cook, F. L.; Bowers, C. W.; Liotta, C. L. Chemistry of "Naked" Anions. III. Reaction of the 18-Crown-6 Complex of Potassium Cyanide with Organic Substrates in Aprotic Organic Solvents. J. Org. Chem. 1974, 39, 3416-3418.
43. Normant, J. F.; Deshayes, H. Utillisation du chlorure de thionyle dans l'hexamethylphosphoramide. Bull. de la Soc. Chim. de France 1972, 2854-2859.
44. Villieras, J.; Rambaud, M. Wittig-Homer Reaction in Heterogeneous Media; 2. A Convenient Synthesis of a,b-Unsaturated Esters and Ketones using Weak Bases in Water. Synthesis 1983, 300-303.
45. Umino, N.; Iwakuma, T.; Itoh, N. Sodium Acyloxyborohydride as New Reducting Agents. II. Reduction of Nitriles to the corresponding Amines. Tetrahedron Lett. 1976, 2875-2876.
46. Tanaka, M.; Chaki, S.; Imagawa, Y.; Okuyama, S.; Muramatsu, M. FH-510, a Potent and Selective Ligand for Rat Brain σ Recognition Sites. Eur. J. Pharmacol. 1993, 238, 89-92.
47. Billard, W.; Ruperto, V.; Crosby, G.; Iorio, L. C.; Barnett, A. Characterization of the Binding of 3H-SCH 23390, a Selective D-1 Receptor Antagonist Ligand, in Rat Striatum. Life Sci. 1984, 5, 1885-1893.
48. 1 binding sites in guinea pig brain. Eur. J. Pharmacol. 1994, 251, R1-R2.
49. Sturgeon, R. D.; Fessier, R. G.; Meltzer, H. Y. Behavioral Rating Scales for Assessing Phencyclidine-induced Locomotor Activity, Stereotyped Behavior and Ataxia in Rats. Eur. J. Pharmacol. 1979, 59, 169-179.
50. Contreras, P. C.; Contreras, M. L.; O'Donohue, T. L.; Lair, C. C. Biochemical and Behavioral Effects of σ and PCP Ligands. Synapse 1988, 2, 240-243.
51. Okuyama, S.; Imagawa, Y.; Ogawa, S.; Araki, H.; Ajima, A.; Tanaka, M.; Muramatsu, M.; Nakazato, A.; Yamaguchi, K.; Yóshida, M.; Otomo, S. NE-100, A Novel σ Recepto Ligand: In Vivo Tests. Life Sci. 1993, 53, PL 285-290.
52. Okuyama, S.; Imagawa, Y.; Sakagawa, T.; Nakazato, A.; Yamaguchi, K.; Yoshida, M.; Katoh, M.; Yamada, S.; Araki, H.; Otomo, S. NE-100, A Novel σ Receptor Ligand: Effect on Phencyclidine-induced Behaviors in Rats, Dogs and Monkeys. Life Sci. 1994, 55, PL133-138.
53. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossmann, H. Purification, molecular cloning, and expression of the mammalian σ 1 - binding site. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-8077.
54. Seth, P.; Fei, Y. J.; Li, H. W.; Huang, W.; Leibach, F. H.; Ganapathy, V. Cloning and functional characterization of a σ receptor from rat brain. J. Neurochem. 1998, 70, 922-931.
55. Lehmann, J. σ receptor, schizophrenia and cytochrome P-450. Drug News Perspect. 1991, 4, 208-210.
56. Abou-Gharbia, M.; Ablordeppey, Y. S.; Glennon, A. R. σ Recptors and their Ligands: The σ Enigma. Annu. Rep. Med. Chem. 1993, 28, 1-9.
57. Okuyama, S. Nakazato, A. NE-100: A Novel σ Receptor Antagonist. CNS Drug Rev. 1996, 2, 226-237.